AlloVir
Jeffrey Bornstein is a Director at AlloVir, and has an education from Northeastern University. He has experience as a Board/Investor at Nucleated Foam Technologies Inc, partner at Whipstick Ventures LLC, Investor at Holobiome.
This person is not in the org chart
This person is not in any offices
AlloVir
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.